Onesource Specialty Pharma Limited (NSE: ONESOURCE, BSE: 544292) is a Bengaluru, Karnataka-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹18,138 Cr, it ranks #389 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 11 in Pharmaceutical CDMO and CRO Services. At ₹1,603.00 (as of 16 Nov 2026), the share price is 16.4% below its 52-week high of ₹1,917.80 and 51.7% above its 52-week low of ₹1,057.00. The share price is down 9.4% over one year and up 2.5% over three months.
| Current Price | ₹1,603.00 |
|---|---|
| Market Cap | ₹18,138 Cr |
| NSE Symbol | ONESOURCE |
| BSE Code | 544292 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -1.26% |
| Return on Assets | -0.03% |
| 52-Week Range | ₹1,057.00 – ₹1,917.80 |
| 1-Year Price Change | -9.4% |
| 3-Month Price Change | +2.5% |
| Beta (1Y) | 0.2 |
| Headquarters | Bengaluru, Karnataka |
| Website | www.onesourcecdmo.com |
| Revenue | ₹516 Cr |
|---|---|
| Net Profit | ₹57 Cr |
| Net Margin | 11.1% |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Onesource Specialty Pharma Limited reported revenue of ₹516 Cr in Q2 FY27, up 37.4% from ₹376 Cr in Q2 FY26 and up 15.0% from ₹449 Cr in Q1 FY27. It posted a net profit of ₹57 Cr for the quarter, against a net profit of ₹10 Cr in Q2 FY26 (up 448.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹290 Cr (Q3 FY26) to ₹516 Cr (Q2 FY27). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹516 Cr | ₹57 Cr | 11.1% |
| Q1 FY27 | ₹449 Cr | ₹25 Cr | 5.6% |
| Q4 FY26 | ₹428 Cr | ₹5 Cr | 1.1% |
| Q3 FY26 | ₹290 Cr | −₹89 Cr | −30.6% |
| Q2 FY26 | ₹376 Cr | ₹10 Cr | 2.8% |
| Q1 FY26 | ₹327 Cr | −₹0 Cr | −0.1% |
| Q4 FY25 | ₹426 Cr | ₹98 Cr | 23.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 30.47% of Onesource Specialty Pharma Limited's shares as of Sept 2026, against 29.77% in Sept 2025 (+0.70 percentage points). Delivery averaged 49.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, I
1. Contract Development & Manufacturing Organization-This segment engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats. 2. Multimodal Facility and CDMO (Discontinued)-This segment engages in the provision of contract development and manufacturing operation services for pre-clinical and clinical development; and manufacture and commercial supply of biologics. 3. Multimodal Facility and CDMO - Discontinued-This segment engages in the provision of contract development and manufacturing operation services for pre-clinical and clinical development; and manufacture and commercial supply of biologics. 4. Segment Adjustment-NA
1. Contract Development & Manufacturing Organization-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Onesource Specialty Pharma Limited is trading at ₹1,603.00, with a market capitalisation of ₹18,138 Cr.
Onesource Specialty Pharma Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Onesource Specialty Pharma Limited has a return on equity of -1.26%.
Onesource Specialty Pharma Limited is listed on the NSE under the symbol ONESOURCE and on the BSE under the scrip code 544292.
Onesource Specialty Pharma Limited's share price is down 9.4% over one year and up 2.5% over three months. Its 52-week range is ₹1,057.00 to ₹1,917.80.
In Q2 FY27, Onesource Specialty Pharma Limited reported revenue of ₹516 Cr and net profit of ₹57 Cr (consolidated, parsed from the company's exchange filing).
Onesource Specialty Pharma Limited reported revenue of ₹516 Cr in Q2 FY27, up 37.4% from ₹376 Cr in Q2 FY26 and up 15.0% from ₹449 Cr in Q1 FY27.
Promoters held 30.47% of Onesource Specialty Pharma Limited's shares as of Sept 2026, against 29.77% in Sept 2025 (+0.70 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.